Skip to main content

New Drug Approvals - Pt. XV - Asenapine (Saphris)

By jpo

On the 14th August 2009 Asenapine (tradename Saphris) was approved for the acute treatment of schizophrenia in adults and acute treatment of manic or mixed episodes associated with bipolar I disorder with or without psychotic features in adults. This class of psychiatric diseases are complex and carry a significant economic healthcare burden; approximately 24 million people worldwide are believed to suffer from schizophrenia, while ca. 67 million people are thought to suffer from bipolar I disorder. Asenapine (previously known by the research code Org-5222) is the one of a large class of drugs aimed at treating such diseases, and shows the typical broad spectrum of against a variety of receptor targets and a complicated mechanism of action, although such drugs are thought to primarily act through antagonism of D2 and 5HT2A receptors. To give some idea of the promiscuity (or polypharmacology) of Asenapine at various aminergic GPCRs, reported pKis are 5HT1A 8.6, 5HT1B 8.4, 5HT2A 10.2, 5HT2B 9.8, 5HT2C 10.5, 5HT5A 8.8, 5HT6 9.5, 5HT7 9.9, alpha1 8.9, alpha2A 8.9, alpha2B 9.5, alpha2C 8.9, D1 8.9, D2 8.9, D3 9.4, D4 9.0, H1 9.0, and H2 8.2. Asenapine has had quite a complex development and commercial history, as web searches will readily show.

Asenapine is a small molecule drug (Molecular Weight of 285.8 g.mol-1 for Asenapine itself, and 401.84 g.mol-1 for the Asenapine Malate dosed ingredient). Asenapine is reasonably absorbed with an absolute bioavailability of 35% for sublingual dosing - for oral dosing (i.e. the drug makes it into the stomach and bowel absorption is far lower at ca. 2%. (This route of absorption also is really 'topical', even through thr drug is orally dosed, hence the topical icon above - confusing -eh?). Asenapine has high plasma protein binding (~95%), and a volume of distribution of 20-25 L.kg-1). It also has a high clearance - 52 L.hr-1. Asenapine is primarily metabolized by oxidative metabolism by CYP1A2 and also by direct glucoronidation by UGT1A4, and is cleared by both renal and hepatic routes in approximately similar proportions. It has a an elimination half-life of ca. 24 hours and due to this long half-life, steady-state plasma concentrations are reached after approximately three days. Recommended dosage is one tablet of 5 mg twice daily (equivalent to ca. 24.9 µmol). The full prescribing information can be found here.

Asenapine has a boxed warning.

The Asenapine structure is (3aRS,12bRS)-5-Chloro-2-methyl-2,3,3a,12b-tetrahydro-1Hdibenzo[2,3:6,7]oxepino[4,5-c]pyrrole - and more broadly is member of a set of molecules called dibenzo-oxepino pyrroles. It is fully rule-of-five-compliant. The structure is reasonably unremarkable in terms of its functional group content - the only distinctive feature is the basic amine, but other than being primarily flat, highly rigid and planar, it is difficult to highlight anything more specific.

Asenapine canonical SMILES: CN1CC2C(C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24 Asenapine InChI: InChI=1S/C17H16ClNO/c1-19-9-14-12-4-2-3-5-16(12)20-17-7-6-11(18)8-13(17) 15(14)10-19/h2-8,14-15H,9-10H2,1H3/t14-,15-/m1/s1 Asenapine InChIKey: VSWBSWWIRNCQIJ-HUUCEWRRSA-N Asenapine CAS registry: 65576-45-6 Asenapine ChemDraw: Asenapine.cdx

The license holder for Asenapine is Schering Plough and the product website is www.saphris.com.

Labels:

Comments

Egon Willighagen said…
That's one nice big pile of facts here. Are you copy/pasting this into Wikipedia too?
16 August 2009 at 16:30
PaulBo said…
I think your drug icon is wrong. Unless this is a new breed of topically administered anti-psychotics ;)

Reminds me of the time a lady in Nepal came up to me and asked for a plaster; she proceeded to stick it on her forehead to treat her headache...
21 August 2009 at 20:47
jpo said…
Well it is a little more complex than that. It is correct that you take the tablet into your mouth, but you slip it under your tongue and don't actually swallow it. So it avoids the stomach, bowel, portal vein, etc., of 'oral' drugs. So in our definition it is topically absorbed. The same would be true for rectally dosed drugs - I think for most workers thinking of drug design, an 'oral' drug would be one that is absorbed via transit through the stomach.
21 August 2009 at 21:19
Unknown said…
I'm having a really good time with these new drug approval blog posts, John. Actually, I like Egon's suggestion although I must say that this can be a real nuisance because it is quite likely that the Wikipedia editors will haunt you with requests for references for all the facts in your article.
26 August 2009 at 11:50
Post a Comment

Popular posts from this blog

Here's a nice Christmas gift - ChEMBL 35 is out!

By
Use your well-deserved Christmas holidays to spend time with your loved ones and explore the new release of ChEMBL 35!            This fresh release comes with a wealth of new data sets and some new data sources as well. Examples include a total of 14 datasets deposited by by the ASAP ( AI-driven Structure-enabled Antiviral Platform) project, a new NTD data se t by Aberystwyth University on anti-schistosome activity, nine new chemical probe data sets, and seven new data sets for the Chemogenomic library of the EUbOPEN project. We also inlcuded a few new fields that do impr ove the provenance and FAIRness of the data we host in ChEMBL:  1) A CONTACT field has been added to the DOCs table which should contain a contact profile of someone willing to be contacted about details of the dataset (ideally an ORCID ID; up to 3 contacts can be provided). 2) In an effort to provide more detailed information about the source of a deposited dat...
Post a Comment
Read more

Improvements in SureChEMBL's chemistry search and adoption of RDKit

By Eloy
    Dear SureChEMBL users, If you frequently rely on our "chemistry search" feature, today brings great news! We’ve recently implemented a major update that makes your search experience faster than ever. What's New? Last week, we upgraded our structure search engine by aligning it with the core code base used in ChEMBL . This update allows SureChEMBL to leverage our FPSim2 Python package , returning results in approximately one second. The similarity search relies on 256-bit RDKit -calculated ECFP4 fingerprints, and a single instance requires approximately 1 GB of RAM to run. SureChEMBL’s FPSim2 file is not currently available for download, but we are considering generating it periodicaly and have created it once for you to try in Google Colab ! For substructure searches, we now also use an RDKit -based solution via SubstructLibrary , which returns results several times faster than our previous implementation. Additionally, structure search results are now sorted by...
Post a Comment
Read more

ChEMBL 34 is out!

By
We are delighted to announce the release of ChEMBL 34, which includes a full update to drug and clinical candidate drug data. This version of the database, prepared on 28/03/2024 contains:         2,431,025 compounds (of which 2,409,270 have mol files)         3,106,257 compound records (non-unique compounds)         20,772,701 activities         1,644,390 assays         15,598 targets         89,892 documents Data can be downloaded from the ChEMBL FTP site:  https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_34/ Please see ChEMBL_34 release notes for full details of all changes in this release:  https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_34/chembl_34_release_notes.txt New Data Sources European Medicines Agency (src_id = 66): European Medicines Agency's data correspond to EMA drugs prior to 20 January 2023 (excluding ...
Post a Comment
Read more

Improved querying for SureChEMBL

By
    Dear SureChEMBL users, Earlier this year we ran a survey to identify what you, the users, would like to see next in SureChEMBL. Thank you for offering your feedback! This gave us the opportunity to have some interesting discussions both internally and externally. While we can't publicly reveal precisely our plans for the coming months (everything will be delivered at the right time), we can at least say that improving the compound structure extraction quality is a priority. Unfortunately, the change won't happen overnight as reprocessing 167 millions patents takes a while. However, the good news is that the new generation of optical chemical structure recognition shows good performance, even for patent images! We hope we can share our results with you soon. So in the meantime, what are we doing? You may have noticed a few changes on the SureChEMBL main page. No more "Beta" flag since we consider the system to be stable enough (it does not mean that you will never ...
Post a Comment
Read more

ChEMBL brings drug bioactivity data to the Protein Data Bank in Europe

By
In the quest to develop new drugs, understanding the 3D structure of molecules is crucial. Resources like the Protein Data Bank in Europe (PDBe) and the Cambridge Structural Database (CSD) provide these 3D blueprints for many biological molecules. However, researchers also need to know how these molecules interact with their biological target – their bioactivity. ChEMBL is a treasure trove of bioactivity data for countless drug-like molecules. It tells us how strongly a molecule binds to a target, how it affects a biological process, and even how it might be metabolized. But here's the catch: while ChEMBL provides extensive information on a molecule's activity and cross references to other data sources, it doesn't always tell us if a 3D structure is available for a specific drug-target complex. This can be a roadblock for researchers who need that structural information to design effective drugs. Therefore, connecting ChEMBL data with resources like PDBe and CSD is essen...
Post a Comment
Read more